ABSTRACT
Introduction: Urinary incontinence affects more than 50 million people worldwide, it has a great impact on quality of life by affecting social, domestic, occupational and sex life, regardless of age. Objective: Theobjective of this study was to analyze the effectiveness of physical therapy treatment in women attending the Urogynecology service of Hospital and Maternity Leonor Mendes de Barros. Method: We retrospectively assessed 65 records of patients with diagnosis of urinary incontinence treated between November 2005 and November 2006. In order to have their data analyzed, patients were divided into two groups; group MF, which underwent medical treatment and physiotherapy, and group M, which had only medical treatment.In order to compare both groups quantitative data, the analysis was performed in Statistica® software usingMann Whitneys non-parametric test. The analysis of association between the quantitative variables was performed through the Chi-Square test at 5% (p ≥ 0.05) significance level. Results: We observed that 60.6% of patients who underwent physical therapy treatment and medical treatment had the urinary incontinence symptoms decreased or completely cured, while 80% of women belonging to the medical treatment only-group underwent surgery. Conclusion: Thus, we conclude that physical therapy is essential in treatment protocols of urinary incontinence outpatient clinics and to prevent surgery.
Subject(s)
Humans , Female , Urinary Incontinence/surgery , Urinary Incontinence/therapy , Physical Therapy ModalitiesABSTRACT
OBJECTIVES/HYPOTHESIS: Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of cases. Good response to hormone treatment has been documented, although its use remains controversial. The aim of this study was to examine the efficacy of an antiestrogenic agent, Tamoxifen, in the treatment of HHT-associated epistaxis. METHODS: Twenty-five patients (11 men, 14 women; mean age 51 years) with a diagnosis of epistaxis due to HHT were randomly assigned to receive treatment with oral tamoxifen 20 mg/d or placebo for 6 months. Follow-up consisted of physical examination and once-monthly blood tests. RESULTS: The groups were similar in age and sex distribution. Of the 21 participants who completed the trial, alleviation of the epistaxis was noted in 9 of 10 tamoxifen-treated patients and 3 of 11 placebo-treated patients (including 2 with only temporary improvement). The difference between the groups at the trial end point was significant for both frequency (P = .01) and severity (P = .049) of the disease. Hemoglobin concentration rose in 4 tamoxifen-treated patients and decreased in 5 controls. CONCLUSIONS: Tamoxifen appears to be an effective agent for the treatment of epistaxis due to HHT.
Subject(s)
Epistaxis/drug therapy , Tamoxifen/therapeutic use , Telangiectasia, Hereditary Hemorrhagic/drug therapy , Administration, Oral , Adult , Aged , Double-Blind Method , Epistaxis/etiology , Female , Humans , Male , Middle Aged , Placebos , Severity of Illness Index , Telangiectasia, Hereditary Hemorrhagic/complications , Treatment OutcomeABSTRACT
Este trabalho teve como objetivo demonstrar a importância do exame citológico de Papanicolaou como exame de rotina nas grávidas atendidas no Serviço de Pré-Natal da Escola Paulista de Medicina, de 1983 a 1989. Correlacionamos em 73 casos, o exame citológico compatível com atipia coilocitótica com os achados colposcópicos e os anatomopatológicos. Em 143 resultados citológicos positivos, 73 (51 por cento) foram submetidos à exame colposcópico (12 apresentaram lesöes condilomatosas). Em 45 (73,8 por cento) dos 61 casos restantes, epitelio branco foi a lesäo colposcópica mais freqüentemente encontrada. Os achados histopatológicos foram a displasia associada a atipia coilocitítica em 36 por cento de displasias e Ca in situ em 18,8 por cento. O estudo ressalta a importância da investigaçäo rotineira através da colposcopia e da biopsia orientada, nos casos de alteraçöes coilocitóticas (HPV) detectadas a luz do exame de Papanicolaou.
